CanSino returned to loss after the new crown vaccine could not be sold and the pre-loss exceeded 800 million

Just before the announcement of the liberalization in December last year, the inhaled vaccine developed by CanSino was launched. The market had expected to improve its performance, but unexpectedly, the inhaled vaccine did not allow CanSino to get rid of losses. The reason is easy to understand. Although inhaled vaccines are easier to vaccinate, according to the feedback from people around them, the side effects are relatively large. In addition, the current vaccines cannot fundamentally prevent virus mutations, which leads to people’s low willingness to vaccinate.

In addition, in December, the vast majority of people were infected before they had time to receive the inhalation vaccine. In fact, there was no re-vaccination within half a year after infection, so even though various experts kept reminding them to take a different vaccine for the fourth dose , implying that everyone should vaccinate CanSino, but in fact the vaccine still cannot be sold.